Discontinued — last reported Q4 '21
Alnylam Pharmaceuticals Valuation Allowances And Reserves Balance increased by 12.1% to $477.04M in Q1 2026 compared to the prior quarter.
An increase may signal management's expectation of higher future losses or a more conservative valuation approach, while a decrease may signal improved asset quality.
This balance represents the total provisions set aside to account for potential losses, impairments, or valuation adjust...
Standard across financial services; peers maintain varying levels of reserves based on the risk profile of their investment portfolios and regulatory requirements.
other_valuation_allowances_and_reserves_balance| Q4 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|
| Value | $361.82M | $473.94M | $559.42M | $425.65M | $477.04M |
| QoQ Change | — | +31.0% | +18.0% | -23.9% | +12.1% |
| YoY Change | — | — | — | +17.6% | — |